Eevia Health Plc ("the Company" or "Eevia") has become aware that one of the Company's shareholders, Futur Pension Holding AB's has an indirect holding via Futur Pension Försäkringsaktiebolag of 672,307 shares in the Company. The holding has decreased from 743,500 shares and the holding now corresponds to approximately 4,82 % of total shares and votes in Eevia.
Seinäjoki, Finland 26.11.2021
For more information, please contact:
Kim Nurmi-Aro, CFO
kim@eeviahealth.com
Tel.: +358 504 44 0717
About Eevia
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild-harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a fast-growing Finnish manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion. Eevia's branded ingredients, such as Feno-Myrtillus® Organic (high concentrate bilberry extracts with 36% anthocyanins) and Fenoprolic® 70 Organic (pine bark extracts with 70% oligomeric proanthocyanidins), are organically certified.
Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.
Eevia Health ("Eevia" or "The Company") received a 13K USD /12KEUR sales order for the elderberry extract Feno-Sambucus™ 7 Organic.
Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the first quarter of 2023.
Eevia Health Abp ("Eevia Health" or the "Company") has appointed Mangold Fondkommission to act as a liquidity provider for the company's shares. The assignment commences on Wednesday, May 4th, 2023.
Eevia Health Plc ("Eevia" or "The Company") has decided to adjust the planned time for several financial events in 2023.
Due to a language setting choice in our Cision News portal with both English and Finnish chosen in the original press release, the press release did not go out automatically on all channels at the same time. To ensure the release is available on all channels, we re-release the press release. There are no changes to the substance of the release.
Eevia Health Plc, ("Eevia" or "The Company"), received several new sales orders totaling c. 23.8 MSEK / 2.1 MEUR from an International nutraceutical brand owner for an extract ingredient with immune health properties.
Eevia Health Plc, ("Eevia" or "The Company"), received several new sales orders totaling c. 23.8 MSEK / 2.1 MEUR from an International nutraceutical brand owner for an extract ingredient with immune health properties.
Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the fourth quarter of 2022.
Eevia Health Plc ("Eevia" or "The Company") is welcoming Matleena Kotila as the new Commercial manager. At the same time, Tommi Kilpeläinen's contract as Scientific Product Manager was discontinued in the trial period.
Eevia Health ("Eevia" or "The Company") received a sales order from a US customer for the elderberry extract Feno-Sambucus™ 7 Organic for a value of just over USD 200k or EUR 187k.
Stein Ulve, the Chief Executive Officer (CEO) of Eevia Health Plc, ("Eevia" or "The Company") has sold 112 782 shares in The Company to Harri Salo, the Chief Manufacturing Officer (CMO) of Eevia.